Phospho-KCNA3 (Y187) Antibody

What is Phospho-KCNA3 (Y187) Antibody and what specific epitope does it recognize?

Phospho-KCNA3 (Y187) antibody is a polyclonal antibody that specifically recognizes the Kv1.3 voltage-gated potassium channel (encoded by the KCNA3 gene) when phosphorylated at tyrosine 187. The antibody is typically generated using a synthesized peptide derived from human Kv1.3 sequence surrounding the phosphorylation site of Y187. This antibody detects endogenous levels of Kv1.3 protein only when phosphorylated at this specific residue, making it valuable for studying post-translational regulation of this channel .

What is the importance of Kv1.3 phosphorylation at Y187 in cellular function?

Tyrosine phosphorylation at position 187 of Kv1.3 represents a critical regulatory mechanism that modulates channel activity and membrane localization. Phosphorylation at this site can affect:

• Channel gating properties and ion conductance

• Protein-protein interactions with scaffolding proteins

• Trafficking between cellular compartments

• Channel inactivation kinetics and voltage-dependent properties

This specific phosphorylation event is particularly important in immune cells where Kv1.3 regulates membrane potential during T-cell activation and proliferation. Alterations in phosphorylation status at Y187 can significantly impact immune cell function and signaling pathways .

What are the recommended applications and dilutions for Phospho-KCNA3 (Y187) antibody?

Based on validated protocols, this antibody can be used in multiple experimental applications with the following recommended dilutions:

These applications have been tested on human, mouse, and rat samples. The antibody has not yet been extensively validated for other applications such as chromatin immunoprecipitation (ChIP) or flow cytometry .

What is the optimal protocol for using Phospho-KCNA3 (Y187) antibody in Western blot experiments?

For optimal Western blot results with Phospho-KCNA3 (Y187) antibody:

• Sample preparation:

  • Include phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride) in lysis buffer

  • Use fresh samples when possible, as freeze-thaw cycles can degrade phospho-epitopes

  • Denature samples at 95°C for 5 minutes in standard Laemmli buffer

• Gel electrophoresis and transfer:

  • Use 8-10% polyacrylamide gels for optimal separation

  • Transfer to PVDF membrane (preferred over nitrocellulose for phospho-proteins)

• Blocking and antibody incubation:

  • Block with 5% BSA in TBST (not milk, which contains phosphatases)

  • Dilute primary antibody 1:1000 in 5% BSA/TBST

  • Incubate overnight at 4°C with gentle rocking

  • Wash 4-5 times with TBST before secondary antibody incubation

• Detection considerations:

  • The expected molecular weight for phosphorylated Kv1.3 is approximately 58 kDa

  • Include positive controls such as stimulated T cells or cells treated with pervanadate

This protocol has been optimized for detecting the phosphorylated form while minimizing background and cross-reactivity .

How can researchers validate the specificity of Phospho-KCNA3 (Y187) antibody?

Multiple validation methods should be employed to ensure antibody specificity:

• Phosphatase treatment controls:

  • Split your sample and treat half with lambda phosphatase

  • A genuine phospho-specific antibody should show decreased or absent signal in the treated sample

• Peptide competition assay:

  • Pre-incubate antibody with excess phospho-peptide immunogen

  • Signal should be blocked by phosphorylated peptide but not by non-phosphorylated peptide

• Genetic validation:

  • Use KCNA3 knockout cells/tissues as negative controls

  • Alternatively, use Y187F mutant expression systems where the tyrosine is replaced with non-phosphorylatable phenylalanine

• Phosphorylation induction:

  • Treat cells with tyrosine phosphatase inhibitors to increase phosphorylation

  • Signal should increase in treated samples

• Correlation with other methods:

  • Verify phosphorylation using mass spectrometry when possible

  • Compare results with alternative phospho-specific antibodies if available

These validation steps are critical for ensuring results reflect true biological phosphorylation events and not non-specific binding .

Does Phospho-KCNA3 (Y187) antibody cross-react with other phosphorylated potassium channels?

Cross-reactivity with related potassium channels is an important consideration. The Kv1 family members (Kv1.1-Kv1.8) share sequence homology, potentially leading to cross-reactivity. Current data indicates:

• The antibody demonstrates highest specificity for phosphorylated Kv1.3 at Y187

• Potential cross-reactivity may occur with Kv1.2 and Kv1.1, which have similar amino acid sequences surrounding equivalent tyrosine residues

• Limited cross-reactivity has been observed with phosphorylated forms of more distantly related channels

To minimize misinterpretation:

• Always include appropriate controls (knockout samples or Y187F mutants)

• Consider sequence alignment analysis to identify potential cross-reactive epitopes

• When possible, confirm findings using complementary approaches such as mass spectrometry

• In tissues expressing multiple Kv channels, validate using pharmacological blockers specific to Kv1.3 (e.g., margatoxin) .

How can Phospho-KCNA3 (Y187) antibody be used to study T-cell activation mechanisms?

Phospho-KCNA3 (Y187) antibody provides a powerful tool for investigating T-cell activation dynamics:

• Temporal phosphorylation dynamics:

  • Monitor Y187 phosphorylation at different time points following T-cell activation

  • Compare with calcium flux measurements and membrane potential recordings

  • Correlate with downstream signaling events like NFAT translocation

• Spatial organization studies:

  • Use immunofluorescence with Phospho-KCNA3 (Y187) antibody to track channel localization

  • Co-stain with markers of the immunological synapse to determine recruitment patterns

  • Employ super-resolution microscopy for detailed spatial distribution analysis

• Signaling pathway integration:

  • Use phospho-Src (Y419) antibodies in parallel, as Src kinases are known to phosphorylate Kv1.3

  • Perform co-immunoprecipitation to identify phosphorylation-dependent protein interactions

  • Apply kinase inhibitors to determine which pathways regulate Y187 phosphorylation

• Functional correlation:

  • Combine phosphorylation detection with patch-clamp electrophysiology

  • Correlate changes in phosphorylation status with alterations in channel conductance

  • Test how mutations at Y187 affect both phosphorylation and channel function

These approaches can reveal crucial mechanisms governing immune cell activation and potential therapeutic targets for immunomodulation .

How does phosphorylation at Y187 affect Kv1.3 channel interactions with other proteins?

Phosphorylation at Y187 can significantly alter the Kv1.3 interactome. Recent research using proximity labeling techniques has identified several proteins whose interaction with Kv1.3 is regulated by Y187 phosphorylation:

• Scaffolding proteins:

  • Phosphorylated Y187 creates binding sites for SH2 domain-containing proteins

  • Interactions with DLG1 (SAP97) are enhanced upon Y187 phosphorylation

  • STIM1 association may be regulated by phosphorylation status

• Trafficking machinery:

  • PICALM and CLINT1 show differential binding based on phosphorylation status

  • Vesicle-mediated transport proteins (RAB6A, CORO1A) interaction is modulated

• Signaling complexes:

  • CD3E interaction in T cells is phosphorylation-dependent

  • Phosphorylated Kv1.3 preferentially associates with components of Golgi transport machinery

Methodologically, studies employ:

• Co-immunoprecipitation with phospho-specific antibodies

• Proximity labeling using TurboID-tagged Kv1.3 variants

• Phosphomimetic mutations (Y187E) versus phospho-deficient mutations (Y187F)

• Mass spectrometry to identify interacting proteins in different phosphorylation states

Understanding these phosphorylation-dependent interactions provides insight into how post-translational modifications regulate channel function and localization .

How is Phospho-KCNA3 (Y187) antibody being used to investigate the newly discovered role of Kv1.3 in neurological disorders?

Recent groundbreaking research has identified de novo variants in KCNA3 associated with developmental and epileptic encephalopathy (DEE). Phospho-KCNA3 (Y187) antibody is playing a crucial role in these investigations:

• Pathogenic variant characterization:

  • Comparing phosphorylation levels between wild-type and disease-associated variants

  • Investigating whether mutations near Y187 affect phosphorylation efficiency

  • Determining if altered phosphorylation contributes to channel dysfunction

• Neuronal expression studies:

  • Mapping phospho-Kv1.3 distribution in neuronal populations

  • Examining developmental changes in phosphorylation patterns

  • Comparing phosphorylation in epileptogenic versus non-epileptogenic brain regions

• Electrophysiological correlations:

  • Analyzing how phosphorylation status affects neuronal excitability

  • Determining whether disease variants show aberrant phosphorylation-dependent gating

  • Testing if pharmacological modulators of Kv1.3 (like fluoxetine) affect phosphorylation

• Potential therapeutic implications:

  • Screening compounds that modulate Y187 phosphorylation as potential therapeutics

  • Determining whether antiepileptic drugs affect Kv1.3 phosphorylation status

  • Investigating whether phosphorylation status can predict response to channel modulators

These studies represent a paradigm shift from viewing Kv1.3 solely as an immune-related channel to recognizing its critical role in neuronal excitability and neurodevelopmental disorders .

What technical challenges exist when using Phospho-KCNA3 (Y187) antibody for studying low-abundance tissues or rare cell populations?

Detecting phosphorylated Kv1.3 in low-abundance tissues presents several technical challenges that require specialized approaches:

• Sample enrichment strategies:

  • Immunoprecipitation before Western blotting to concentrate target protein

  • Cell sorting to isolate specific populations expressing Kv1.3

  • Proximity ligation assay (PLA) for increased sensitivity in tissue sections

• Signal amplification methods:

  • Tyramide signal amplification for immunohistochemistry/immunofluorescence

  • Highly sensitive ECL substrates for Western blotting

  • Quantum dot-conjugated secondary antibodies for improved signal-to-noise ratio

• Phosphorylation preservation:

  • Rapid tissue processing to prevent phosphatase activity

  • Use of phosphatase inhibitor cocktails optimized for tyrosine phosphorylation

  • Special fixation protocols for maintaining phospho-epitopes in tissue samples

• Controls and validation:

  • Paired phospho-specific and total Kv1.3 antibodies to normalize signals

  • Inclusion of positive control samples with known high levels of Y187 phosphorylation

  • Multi-method validation using alternative techniques like Phos-tag gels

• Quantification considerations:

  • Digital imaging with standardized exposure settings

  • Internal loading controls specific for phosphorylated proteins

  • Ratiometric analysis comparing phospho-specific to total protein signals

These technical approaches can overcome the challenges of studying phosphorylation events in tissues where Kv1.3 expression is limited or in rare cell populations where traditional methods lack sensitivity .

What are common issues when working with Phospho-KCNA3 (Y187) antibody and how can they be resolved?

Researchers often encounter several challenges when working with phospho-specific antibodies. Here are common issues with Phospho-KCNA3 (Y187) antibody and recommended solutions:

Additionally, researchers should consider basal phosphorylation levels, which may vary by cell type and activation state. In some cases, stimulation protocols may be necessary to achieve detectable phosphorylation .

How should researchers interpret conflicting results between phosphorylation status and functional channel measurements?

When phosphorylation data from antibody-based detection conflicts with functional electrophysiological measurements, consider these interpretative frameworks:

• Stoichiometry considerations:

  • Partial phosphorylation may be sufficient for functional changes

  • Antibodies detect bulk phosphorylation while patch-clamp measures individual channel properties

  • Quantify the ratio of phosphorylated to total Kv1.3 for more accurate correlation

• Spatial and temporal dynamics:

  • Phosphorylation may be transient while functional effects persist

  • Subcellular localization of phosphorylated channels may differ from non-phosphorylated channels

  • Consider using time-resolved approaches to track phosphorylation and function simultaneously

• Multifactorial regulation:

  • Multiple phosphorylation sites may exist beyond Y187

  • Other post-translational modifications may interact with Y187 phosphorylation

  • Channel function may depend on the combined effect of several modifications

• Technical reconciliation approaches:

  • Perform site-directed mutagenesis (Y187F vs. Y187E) to establish causality

  • Use pharmacological modulators that target specific kinases/phosphatases

  • Employ single-molecule approaches to correlate phosphorylation with function at the individual channel level

• Biological context variations:

  • Cell type-specific signaling machinery may affect the relationship between phosphorylation and function

  • Heteromeric channel assembly with other Kv subunits may influence how phosphorylation affects function

  • Membrane microenvironment might modulate the functional consequences of phosphorylation

These considerations provide a framework for resolving seemingly contradictory data between biochemical detection of phosphorylation and functional measurements .